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Abstract Patients with blood disorders (including leukaemia,
platelet function disorders and coagulation factor deficiencies)
or acute bleeding receive blood-derived products, such as red
blood cells, platelet concentrates and plasma-derived prod-
ucts. Although the risk of pathogen contamination of blood
products has fallen considerably over the past three decades,
contamination is still a topic of concern. In order to counsel
patients and obtain informed consent before transfusion, phy-
sicians are required to keep up to date with current knowledge
on residual risk of pathogen transmission and methods of
pathogen removal/inactivation. Here, we describe pathogens
relevant to transfusion of blood products and discuss contem-
porary pathogen removal/inactivation procedures, as well as
the potential risks associated with these products: the risk of
contamination by infectious agents varies according to blood
product/region, and there is a fine line between adequate in-
activation and functional impairment of the product. The cost
implications of implementing pathogen inactivation technol-
ogy are also considered.
Keywords Pathogen . Inactivation . Virus . Removal .
Blood . Clotting . Bleeding disorder . Infection risk . Patient
information
Introduction
Bleeding episodes can occur as a result of trauma, surgery,
internal lesions (e.g. ulcers), infection (e.g. hemorrhagic fe-
ver), anticoagulant medication or the presence of inherited/
acquired bleeding disorders such as coagulation factor defi-
ciencies, thrombocytopenia and platelet function disorders.
Such episodes are often prevented/treated using blood- and
plasma-derived products. In previous decades, the life expec-
tancy of repeatedly transfused patients was much shorter and
mortality much higher due to a lack of effective treatments and
the potential for transfusion-transmitted infections (TTIs) [1,
2]. Significant improvements in the manufacture and use of
blood products have contributed to increased safety and pa-
tient survival [3, 4]. For example, the life expectancy of pa-
tients with haemophilia is now approaching that of the normal
population.
Among the many improvements in the manufacture of
blood products, the decreased risk of pathogen contamination
is of particular importance [5]. As a result of this, the
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transmission of infectious agents via transfusion of blood and
blood derivatives occurs very rarely nowadays in resource-
rich countries (defined as countries with a gross national in-
come per capita (GNI) ≥$12,616) [6, 7]. Recent international
data on transfusion-transmitted viral and bacterial infections
are provided in Table 1. In particular, the risk of transmitting
hepatitis B virus (HBV), hepatitis C virus (HCV) or human
immunodeficiency virus (HIV-1) transmission is minimal;
HBV/HIV TTI was not reported at al l in recent
haemovigilance reports from France, Germany, Italy, Spain
or the UK/USA, while rates of HCV and HEV were low in
general (Table 1) [8–13], and also low in donations [8, 12, 14].
However, physicians still need to be knowledgeable about the
potential risks of TTI to optimize product use, provide accu-
rate information to patients and take appropriate action in case
of suspected infection.
Blood and blood-derived products that are routinely used
in clinical practice include erythrocytes/red blood cells (RBC),
thrombocytes/platelets (PC; for thrombocytopenia and platelet
function disorders), therapeutic plasma (for multiple coagula-
tion factor deficiencies) and plasma-derived coagulation fac-
tors (for individual/combined coagulation factor deficiencies)
[15–17]. Whole blood is no longer routinely used in resource-
rich countries to treat bleeding disorders, but is still occasion-
ally used for acute bleeding episodes [16]. Separation of
whole blood donations into blood-derived cellular compo-
nents and plasma allows resources to be used more efficiently,
since patients requiring platelets (for example) may not re-
quire RBC or clotting factor concentrates, and those compo-
nents can then be redirected to the patient group where they
are needed [18]. In resource-rich countries, 91% of collected
blood is separated into components, compared with 72% and
31% in middle-income (GNI ≥$1036) and lower-income
(GNI ≤$1035) countries, respectively [6, 7]. Separation of
blood in this manner also allows for pathogen reduction/
inactivation procedures to be more readily implemented. A
number of steps are taken to reduce the risk of pathogen trans-
mission: rigorous donor selection, testing for the presence of
pathogens and pathogen inactivation (Fig. 1). This stepwise
reduction in pathogen risk transmission improves the safety of
blood-derived products, although the risk can never be alto-
gether eradicated. There remains an overlap between adequate
inactivation and degradation of beneficial components of the
product [19].
The risk of pathogen contamination of blood products has
fallen considerably over the past three decades, and is current-
ly very low. For example, the residual risks for transmission of
HBV, HIV-1 or HCVare approximately 1 in 500,000, 1 in 2–4
million and 1 in 8–10 million respectively in resource-rich
countries [20–22]. However, it is important to note that the
level of contamination risk varies according to country and
blood product [16]; the emergence of new regional pathogens
(e.g. Zika virus, which has already caused transfusion-
transmitted infection in Brazil [23]) is unpredictable and could
cause harm before local authorities develop means to detect
and prevent blood-borne transmission. This is exacerbated by
the fact that the implementation of pathogen reduction/
inactivation methods varies between countries, due to differ-
ences in national blood collection methods, local resources
and guidelines.
When considering the best course of treatment for patients
with bleeding episodes, physicians should consider patient’s
age, treatment urgency and also the potential risk of TTI. This
suggests a need for physicians (and other health care profes-
sionals) to have a good understanding of the source and
mode(s) of preparation of the products that they use to treat
their patients, including details of blood component produc-
tion (e.g. plasma-derived or recombinant factors) and patho-
gen reduction/inactivation techniques. This review describes
the types of blood and plasma-derived products available and
briefly discusses the different pathogen reduction/inactivation
procedures used in their preparation. Recommendations for
communicating this information to patients when explaining
risks and benefits of treatments are also discussed.
Methodology
The PubMed database was searched over the date range
January 2000–February 2017, using the search strings ‘path-
ogen AND inactivation AND blood’. Additionally, the search
terms ‘reduction’, ‘safety’, ‘haemophilia’, ‘hemophilia’,
‘clotting disorders’, ‘component inactivation’, ‘blood patho-
gen transmission’ and ‘blood AND product AND inactiva-
tion’ were applied. Individual searches were conducted for
information on different aspects of blood collection and prod-
uct treatment. Relevant references were added by the authors,
who also provided additional information, experiences and
opinions which were incorporated in the text.
Separation of blood into components for treatment
of bleeding disorders
Whole blood is separated as needed into cellular products,
including RBC, PC and granulocyte concentrates (GC).
Additional products are fresh frozen plasma (FFP) and
plasma-derived products, including cryoprecipitate (rarely
used in resource-rich countries at the current time) and clotting
factor concentrates (e.g. fibrinogen, prothrombin complex and
factors such as VIII, IX and XIII). Albumin and immunoglob-
ulin concentrates are not routinely involved in the treatment of
bleeding disorders, and do not transmit infectious agents;
therefore, these are not further discussed [15–17, 24, 25].
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Preparation of blood-derived cellular products
The process of separating whole blood donations into cellular
components, with details of particular separation methods, is
shown in Fig. 2; the different storage conditions for each
blood-derived product are indicated in this figure. Whole
blood donations from the UK are not processed in some coun-
tries (e.g. Australia, USA) due to the potential risk of prion
contamination [26, 27].
Storage methods for whole blood (also known as ‘fresh’
blood) and PC vary. Whole blood can be stored for 24 h at a
temperature of 20–24 °C [28–30], but is no longer utilized for
transfusion in resource-rich countries due to the potential risk
due to bacterial transmission and post-transfusion
hypervolemia. The process of separation of whole blood
should therefore be started within 24 h of collection (as de-
tailed in Fig. 2). PC may be stored for 4–5 days at 20–24 °C,
buffered and under permanent motion to preserve cell viability
[24, 31–33]. It should be noted that storage of PC at this
temperature will increase the risk of bacterial growth, as PC
are at risk of bacterial contamination from donor bacteraemia
or skin flora.
The initial step of whole blood processing by centrifu-
gation involves the separation of cells based on their den-
sity, yielding RBC, white cells (buffy coat) and plasma
[34]. Following centrifugation of whole blood, two
methods are routinely used to continue the separation pro-
cess—the buffy coat method and the platelet-rich plasma
(PRP) method. The buffy coat method involves the separa-
tion of whole blood by high-speed centrifugation into RBC,
white cells/platelets and plasma, while the PRP method
involves the low-speed centrifugation of whole blood, leav-
ing a larger proportion of platelets suspended in plasma.
This platelet-rich plasma is then separated from the other
blood components [16, 34].
Following the centrifugation of non-filtered whole blood,
RBC and plasma are separated from the buffy coat, resulting
in leukoreduction (i.e. total leukocyte number ≤0.1–1.2 × 109
per bag). The leukocyte level of plasma and RBC can then be
lowered further by an additional filtration step, after which
they are referred to as leukodepleted (i.e. total leukocyte num-
ber <1.0 × 106 per unit) [16]. The process of leukodepletion is
mandatory in most resource-rich countries; the individual
components prepared from leukodepleted whole blood do
not require further leukocyte removal procedures [16].
Removal of leukocytes can reduce the risk of pathogen
transmission, as leukocytes are potential carriers of pathogens
such as cytomegalovirus (CMV), human T-lymphotropic vi-
rus type 1 (HTLV-1), proteinaceous infectious agents (prions)
and bacterial species such as Listeria and Coxiella. The pro-
cess of leukocyte removal also reduces the risk of transfusion-
associated lung injury (TRALI) and alloimmunization to hu-
man leukocyte antigens (HLA) in recipients [5, 16].
Pathogen transmission risk of blood-derived cellular products
Common strategies for reducing the risk of pathogen trans-
mission include (a) using a pre-donation sampling bag during
initial blood withdrawal to reduce skin flora contamination
[35], (b) shortening the maximum permitted storage time for
PC from 5 to 4 days, (c) subjecting stored PC to screening tests
for the presence of bacterial contamination after 24 h (e.g.
culturing under aerobic and anaerobic conditions, or using
flow cytometry [36–38]) and (d) carrying out pathogen
reduction/inactivation procedures, e.g. treatment with
amotosalen/UVA [4] or other agents. However, these
Fig. 1 Stepwise reduction of
pathogen transmission risk.
Bacterial presence is routinely
tested in platelet concentrates
(PC) by anaerobic and aerobic
cultures or by flow cytometry
(discussed in the Preparation of
blood-derived cellular products
section). The applicability of
purification and inactivation
processes is limited, and is not yet
possible for red blood cells
(RBC). NAT nucleic acid testing.
This figure was designed by the
authors
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measures are not always sufficient to prevent pathogen trans-
mission; bacterial contamination has previously been respon-
sible for fatal septic transfusion reactions, even when present
at concentrations undetectable to screening methods (e.g.
Staphylococcus epidermidis) [39].
It should also be noted that plasma may contain various
viral species (such as hepatitis E virus (HEV), pegivirus,
picornaviridae, etc. [40]) which are not routinely screened
for. The relevance of these pathogens to human health is well
defined in some cases, but still under investigation in others.
Therefore, pathogen inactivation/reduction procedures are
recommended before such products are utilized further [41,
42]. As previously noted, the processes of leukoreduction/
leukodepletion reduce the risk of pathogen transmission, but
do not eliminate it [16].
Preparation of plasma-derived products
Cell-free plasma is usually frozen at −25 °C within 24 h of
collection and is then referred to as fresh frozen plasma. FFP
may be stored for 36 months, during which time it can be
unthawed (usually at 4 °C) for use in transfusion [24, 33].
FFP can also be quarantined for several months, at which
point the donor is re-screened to confirm the absence of path-
ogens; this procedure is preferred in some blood banks (e.g. in
Germany) as it overcomes the problem of donation in the
diagnostic window period when infection is not yet detectable
by antibody/nucleic acid testing [43] and to avoid loss of
clotting factor activity by the inactivation process. Plasma-
derived coagulation factors are prepared from pooled dona-
tions by a multi-step procedure including precipitation and
Fig. 2 Schematic depicting methods for the separation and storage of
blood-derived cellular products and plasma. a Platelet-rich plasma is
produced by separation of RBC followed by leukoreduction. b Buffy
coat is obtained after separation of plasma and the platelet and
leukocyte enriched cell fraction from RBC either from one individual or
from pooling several donations followed by leukoreduction to get PC. c
General overview of blood processing after donor selection and testing.
RBC is always provided by individual donation, while a pool of 4–6
blood donations or plasmapheresis is used for preparation of PC.
Between 1000 and >10,000 plasma donations are pooled for protein
preparation as FVIII and FIX [24, 25]. Non-UK plasma is used in all
countries to avoid the risk of prion contamination; in the UK, non-UK
plasma is used for patients born after 1 January 1996 [24]. HBV hepatitis
B virus, HCV hepatitis C virus, HIV human immunodeficiency virus,
HTLV-1 human T-lymphotropic virus type 1. This figure was adapted
from the Handbook for Transfusion Medicine, 5th Edition [24] and
Vassallo and Murphy 2006 [25]
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chromatography. The prepared factors might be kept for up to
10 days at 1–6 °C, but are usually lyophilized and can be
stably maintained in this state for 6–36 months at 4 °C, or
for a shorter duration if stored at 25 °C [31, 32].
Pathogen transmission risk of plasma-derived products
Plasma may contain a wide variety of micro-organisms, in-
cluding viruses, bacteria, protozoa, microfilaria and prions;
there is potential for viral and bacterial pathogens to be
retained within FFP, cryoprecipitate or less frequently purified
coagulation factors. The processes of filtration, freezing/
thawing and component isolation (e.g. fractionation of coag-
ulation factors) reduce the pathogen load, but do not
completely remove all potential contaminants [19].
Therefore, inactivation processes are considered to be essen-
tial to enhance the safety of these products [44].
Preparation of recombinant clotting products
Aside from plasma-derived clotting factors, recombinant con-
centrates have been available for factors VIIa, VIII, IX and
XIII since the early 90s [45–50] and a recombinant von
Willebrand factor (VWF) concentrate has recently been ap-
proved by the FDA [51]. Recombinant coagulation factors are
stored in a lyophilized state and can maintain full activity for
up to 30 months at 5 °C (reduced activity maintained up to
30 °C) [44]. Recombinant products are not derived from hu-
man blood, but are cloned proteins, maintained in the presence
of stabilizers, such as albumin or other substances, that may be
added duringmanufacture [52–54]. Recombinant products are
classed according to the level of exposure to human plasma or
albumin during their preparation. The most recently produced
recombinant products (‘third-generation’ products) are pro-
duced in the complete absence of blood-derived components
[45–47, 55].
Pathogen transmission risk of recombinant products
There are no known cases of pathogen transmission via the
use of third-generation recombinant products, although exter-
nal contamination of these products might still occur [56].
Recombinant products are therefore subject to at least one
pathogen inactivation procedure. Processes such as chroma-
tography, filtration/nanofiltration, solvent-detergent (SD) and
dry heat treatment are regularly used in the manufacture of
recombinant products and contribute to inactivation of patho-
gens that might be present [52, 54, 57].
What should we say to the patient? It should be noted that
in resource-rich countries, the application of cellular and
plasma-derived products in blood transfusion has never been
safer than it is today, even if no inactivation procedures are
conducted. Purified clotting factors (whether plasma-derived
or recombinant) produced in these countries have very limited
potential for microbial transmission. However, the risk of pri-
on transmission via pooled plasma preparations cannot be
totally discounted.
Techniques for pathogen reduction/inactivation
As discussed, blood safety has improved with the implemen-
tation of more stringent donor selection and antibody/nucleic
acid testing. The World Health Organization (WHO) recom-
mends that all blood donations are screened for the presence
of HIV, HBV, HCV, syphilis and further pathogens as re-
quired, e.g. HTLV-1 [19]. Unfortunately, the completion of
questionnaires by donors cannot prevent transmission of an
infectious agent if donors are unaware that they are infected
[58]. Therefore, current blood collection procedures include a
sampling step where donated blood is screened for pathogen
contamination; donated blood which tests positive at this stage
is excluded from transfusion. There is currently no routine
method for inactivation of pathogenic micro-organisms in
whole blood [4]; however, a recent study performed in
Ghana showed efficient inactivation of Plasmodium
falciparum in transfusion bags treated with riboflavin +
UVB light, indicating that there is hope for progress in this
area [59].
Measures to reduce or inactivate pathogens in blood- and
plasma-derived products vary in their complexity. One simple
method relies upon postponing refrigeration of donated whole
blood, which allows microbes to be phagocytosed and
destroyed by leukocytes within the donation bag; leukocytes
are subsequently removed from the bag via filtration [16].
Storage of blood at 4 °C for longer than 24 h will inactivate
some bacterial species (e.g. Treponema pallidum), but
other species (e.g. Listeria monocytogenes, Yersinia
pseudotuberculosis) are still capable of growth at this temper-
ature and may induce septic shock when transfused with RBC
[60, 61]. Therefore, the refrigeration method does not fully
eradicate pathogenic contamination.
Chemical and photodynamic treatment procedures
Chemical/dynamic treatments rely upon the interaction of a
chemical agent with nucleic acids; this interaction can be trig-
gered by UV light (e.g. amotosalen [S59] or riboflavin) or
adaptation of pH and glutathione (e.g. amustaline [S303], a
nucleic acid alkylator similar to amotosalen [62, 63]). This
interaction causes irreversible damage to nucleic acids, there-
by reducing the level of viable pathogenic contaminants [64,
65]. Photochemical (PhC) methods employ chemical agents
that form a permanent linkage with RNA/DNAwhen exposed
to light, whereas photodynamic (PhD) methods use chemical
agents that simultaneously damage DNA and impede DNA
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repair processes [42, 63, 65, 66]. PhC and PhD technologies
vary in their ability to reduce the level of pathogen contami-
nation. They are generally effective against enveloped viruses,
bacteria and protozoans, but are less reliable for the inactiva-
tion of non-enveloped virus; bacterial spores and prions are
not affected by these methods. The formation of relevant
neoantigens in plasma proteins has not been observed after
PhC/PhD treatment [67–72].
Amotosalen/UVA light
This procedure (INTERCEPT™; Cerus, USA) employs the
combination of a photosensitive agent (amotosalen) and UVA
light and can be used for blood-derived cellular products as
well as plasma and plasma-derived products. It is currently
available in Europe, Australia and North America, and is the
only pathogen reduction system licenced in those countries
[69, 72]. After the inactivation process, the amotosalen must
be completely removed, due to its genotoxicity once exposed
to UVA light [73]. Studies have shown that both plasma and
platelets may be safely and effectively treated with
amotosalen/UVA [71, 74–77], and several countries utilize
this method for pathogen inactivation of plasma [78]. The
method has recently been shown to inactivate Dengue and
Zika virus [77, 79]. Results from prospective randomized
studies have raised questions about the ability of amotosalen +
UVA treatment to reduce pathogen transmission and its impact
on platelet function [80–82], as the life span and clot forma-
tion of platelets might be impaired. Their relevance after PC
transfusion is still a subject of discussion [83, 84]. This is
discussed further in the ‘Risks associated with pathogen
reduction/inactivation treatments‘ section
Amustaline (S303)/glutathione
A combination of the chemical S303 and quencher glutathione
can be used to treat RBC components. S303 is designed to
intercalate into nucleic acids and react with DNA/RNA bases
prior to breaking down to the non-reactive product S300 at
neutral pH; S300 is then bound by glutathione, quenching the
reaction [62]. This method is effective for platelet treatment
and has been shown to successfully inactivate the Zika virus in
whole blood [85] but is still under development in clinical
trials [86, 87].
Riboflavin/UVB light
The Mirasol™ Pathogen Reduction Technology System
(Terumo BCT, USA) uses riboflavin and UVB light to treat
blood-derived cellular products as well as plasma and plasma-
derived products. After the inactivation process, riboflavin
(vitamin B2) does not need to be removed from the treated
product. The procedure is safe and is not toxic or carcinogenic
[65, 67, 70], but may be associated with undesirable side ef-
fects such as expression of active GPIIb/IIIa on platelets and
abnormal interaction of fibrinogen [88]. This method has re-
cently been shown to efficiently inactivate dengue virus in
platelet concentrates [89], ebola virus in vitro [90] and
P. falciparum in whole blood, as described above [59].
Riboflavin/UVB is still in the process of ongoing clinical trials
[91] and has not yet been licenced.
Chemical/photodynamic treatment procedures specifically
for plasma and plasma-derived products
Methylene blue + light This was the first photochemical
pathogen reduction method, described in 1991 and employs
the dye methylene blue in conjunction with visible light [64,
75]. Methylene blue + light (MB-L) is still widely used for
pathogen reduction of therapeutic plasma in Europe (e.g.
Maco-Tronic®; Macopharma, France), but is no longer used
in some countries due to concerns about the potential risk of
MB accumulation and allergic reactions in multi-transfused
patients [69, 75, 92].
UVC light This procedure involves irradiation with UVC
light alone (developed byMacopharma (France)), but the pro-
cedure is not as effective as methods employing amotosalen or
riboflavin in conjunction with UV light. Moreover, this meth-
od is still in the clinical trial phase and has not been certified
suitable for widespread use. The increased energy content of
UVC light means that it can potentially be harmful to clotting
components and may have a negative impact on coagulation
[66, 69, 71].
Solvent-detergent treatment The solvent-detergent (SD)
process is used to treat plasma, but is not suitable for use with
cellular products as the nature of the chemicals used means
that the membranes of cells such as platelets or RBC are
destroyed. The successful use of the SD process to reduce
the level of pathogens in blood products was first described
in 1986 [92–96]. During the SD process, pre-filtered plasma is
treated with an organic solvent (e.g. tri-[N-butyl]-phosphate
(TNBP)) and a detergent (e.g. 1% polyoxyethylene-p-t-
octylphenol; Triton X-100 or Tween 80); the solvent removes
lipids from viral and bacterial membranes and the detergent
disrupts lipid bilayers. The combined action of the solvent and
detergent therefore results in the inactivation of enveloped
viruses present in the plasma [75, 94]; SD must subsequently
be removed from the inactivated product, however. To further
reduce the risk of blood-borne transmission of non-enveloped
viruses in plasma that has undergone SD treatment, compo-
nents are often purified (e.g. via chromatography), and (after
lyophilization) subjected to a second inactivation step such as
heat treatment [64, 97].
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Filtration/nanofiltration
These methods are used exclusively for plasma-derived puri-
fied products; after filtration with a 220-nm or 15- to 50-nm
filter (filtration/nanofiltration, respectively), these products
are considered to be free from bacteria and protozoans such
as Plasmodium, Trypanosoma or Leishmania. However, con-
tamination with small viruses and prions remains a primary
safety concern [19].
Prion reduction
There is currently no widely available reduction/inactivation
method that is capable of completely removing prions from
blood-derived products while maintaining functionality, but
potential alternative solutions are already being implemented.
Leukoreduction of red blood cells for transfusion was intro-
duced in the UK in 1999 to reduce the risk of variant
Creutzfeldt-Jakob Disease (vCJD) transmission by blood
transfusion. Animal studies have shown that leukoreduction
provides a high, but not complete, reduction of the risk of
prion transmission by blood [98]. It is also noteworthy that
the four cases of transfusion-associated vCJD transmission in
the UK all occurred in recipients of non-leukoreduced RBC
concentrates. More recent efforts to increase the efficiency of
prion removal in blood have focused on the development of
prion removal filters. However, most of these filters have been
evaluated on blood spiked with hamster brain infected with a
scrapie-derived prion strain (263K) [98–100]. It is highly un-
likely that the physicochemical properties of these brain-
derived prion spikes mimic those of prions in the blood of
individuals infected with vCJD. A recent evaluation of a prion
filter on blood from primates endogenously infected with
vCJD found some evidence of efficacy, but vCJD transmis-
sion occurred in one primate following transfusion of ‘prion
filtered’ leukoreduced RBC [99]. Further improvement and
evaluation of prion filters is required, but as yet there is no
initiative to introduce the use of currently available prion fil-
ters in the UK or elsewhere. The incidence of vCJD cases in
the UK is declining [101], and thus the risk of prion transmis-
sion by transfusion is very low. Any residual risk might be
further reduced by incorporating recent advances in vCJD
prion detection in a test for blood donor screening [102, 103].
What should we say to the patient? There are various pro-
cedures available which are capable of inactivating protozoan,
bacterial and enveloped viral species, in both PC and plasma
products. Non-enveloped viruses might survive these proce-
dures (dependent on their structure/concentration), but are not
currently considered to pose any significant risk. If a high
level of safety is required, inactivated products should be used
for transfusion. Although a reliable means of removing prion
contamination is not yet available, the overall risks of prion
transmission are very low (even in the UK).
Risks associated with pathogen reduction/inactivation
treatments
The overall risk of pathogen transmission is reduced when
pathogen reduction/inactivation treatments are applied to
blood- and plasma-derived products. However, other risks
are also associated with these treated products: key concerns
include neoantigen formation, loss of product functionality/
activity and the potential link between product use and ad-
verse events in some patients [19, 64].
Neoantigens may be formed in treated blood-derived prod-
ucts due to changes in the three-dimensional structure of pro-
teins, or from cellular debris. When denatured blood-derived
cellular products and plasma-derived products are transfused
into patients, there is a risk that the patient may develop anti-
bodies to the neoantigens present and ultimately will be un-
able to maintain the course of treatment. Antibodies to thera-
peutic proteins are referred to as inhibitors. As a result of
forming inhibitors towards a modified structure of a therapeu-
tic protein (i.e. one which has undergone pathogen inactiva-
tion processing), there is a risk that patients may alsomount an
immune response against unmodified versions of the same
protein, thus preventing effective replacement therapy [104],
as observed, for example, in FVIII-treated patients with
haemophilia A [2].
The risk of inhibitor formation with recombinant clotting
factor concentrates was recently assessed in a study in 251
previously untreated patients, when patients were treated with
either plasma-derived FVIII concentrate containing VWF, or
recombinant FVIII to compare the risk of inhibitor formation
between the two different types of FVIII products [105].
Patients receiving recombinant FVIII displayed significantly
higher levels of inhibitor development compared with patients
who received plasma-derived FVIII/VWF (cumulative inhib-
itor incidence of 44.5% vs. 26.8%, respectively; high-titre
inhibitor incidence in 28.4% and 18.6%, respectively).
However, the difference appeared to be maximally related to
transient inhibitors: when the latter were removed from the
analysis, the difference in inhibitor formation was no longer
statistically significant. In addition, the results of this study
differ from previously published studies which showed
lower/minimal increase in inhibitor formation with recombi-
nant FVIII [106, 107]. It is thought that differences in trial
design may have played a role in this discrepancy between
current and previous results.
Another limitation of pathogen inactivation processes is the
reduction in the activity of products. For example, SD treat-
ment can cause a reduction in FVIII activity in plasma-derived
products; FVIII treated with SD (Octaplas®, Octapharma) has
a FVIII activity level ~10–20% lower than that observed in
FFP. Process validation studies conducted in three European
blood centres showed that PhC-treated plasma displayed a
~26% reduction in FVIII activity compared with that of FFP
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[94]. The activity level of other coagulation factors was also
reduced, but to a lesser extent with clotting factor activity
generally reduced by less than 20% [108]. Compared with
FFP, SD-treated plasma displayed reduced activity levels for
VWF and Protein S (67–76% and 35% reduction, respective-
ly), while MB-L-treated plasma displayed lower fibrinogen
activity levels (approximately 20% reduction) [94, 104, 109].
There have been various reports linking pathogen
inactivated products with adverse events. As mentioned,
use of MB-L-treated plasma has been associated with
post-transfusion anaphylactic reaction, and a study of plas-
ma use in one hospital over several years showed that pa-
tients who received MB-L-treated plasma required 56%
more plasma in total than patients who received non-
inactivated plasma; the increased need for plasma in this
instance was described as an adverse event, but could also
potentially indicate reduced therapeutic efficacy of the
MB-L-treated plasma [104]. MB-L-treated plasma, but
not SD-treated plasma, may also contain residual RBC or
cell fragments, which increase the risk of red cell
alloimmunization; it is still unclear whether the presence
of these residual elements is influenced by the nature of
plasma processing prior to inactivation [104, 110–112].
Concerns have previously been raised over reports of a
potential link between SD-treated plasma and increased
risk of venous thromboembolism, potentially caused by
low levels of Protein S, leading to an increased risk of clot
formation [94, 113]. However, a recent study, and the re-
sumption of SD-treated plasma use in the USA, indicates
that the association of a potential link is still uncertain
[114]. There has been no reported association between
SD treatment and TRALI, which can be a major cause of
transfusion-related mortality using plasma components
containing leukocyte-directed alloantibodies (5–25% of
cases are fatal) [20]. This is thought to be due to low levels
of human leukocyte antigen antibodies, the key mediators
of TRALI, in SD-treated plasma caused by the pooling and
dilution process [104].
What we should say to the patient: Inactivation of infectious
agents improves the safety profile of blood-derived products.
For purified plasma proteins, two inactivation procedures (based
on different inactivation principles) are usually combined.
Inactivation procedures that alter the structure of components
of infectious agents might also affect the natural shape of pro-
teins and cause new epitope (neoantigen) formation on some
proteins, leading to a subsequent immune reaction that may
impair the activity of that protein (e.g. affecting coagulation, in
the case of an enzyme involved in the coagulation cascade). All
pathogen inactivation procedures have some unwanted effects
on the product; on the other hand, lack of treatment may have
fatal consequences due to the survival of infectious agents.
These situations must be evaluated individually, while still con-
sidering the possibility of (rare) side effects.
Cost considerations
Ideally, pathogen reduction/inactivation should be widely ef-
fective, inexpensive and not cause any reduction in the func-
tionality or activity of the product(s) [69]. Practically, the aim
is to reduce the pathogen transmission risk of the final product
as much as possible while avoiding a significant loss of
clotting factor activity which could result in an increase in
cost. The potential cost of treating conditions caused by, or
linked to, pathogen reduction/inactivation procedures should
also be considered [104]. It is difficult to predict the costs
associated with any newly emerging diseases, as there are
many factors to take into account (including the cost of mor-
bidity/mortality, loss of earnings, reduction of productivity,
etc). For example, retrospective analyses of the economic im-
pact of infectious diseases such as dengue fever have not yet
provided a clear picture of their overall cost [115, 116].
Expenditure on medical research should also be considered.
The detection of emerging viruses and the development of an
effective response to reduce the risk of transmission (e.g. West
Nile Virus in 1999, Chikungunya in 2008, Zika virus in 2016)
has resulted in additional expenditure on research and diag-
nostics, and has also historically been responsible for the loss
of blood donations from affected regions [117–119].
Logically, routine implementation of pathogen reduction/
inactivation technology would lower the risk of infection
caused by novel blood-transmissib le pathogens.
Furthermore, if highly effective pathogen reduction/
inactivation procedures were in place, there would be reduced
need for additional expenditure on research and the loss of
donors and their donated blood could be kept to a minimum
[64, 92]. It must however be noted that although routine im-
plementation of pathogen reduction/inactivation technology
would (theoretically) lower the risk of transmission of novel
blood-borne pathogens, the cost-effectiveness of implementa-
tion and potential risks to the quality of life of the recipient
should also be taken into consideration. The main benefit of
pathogen inactivation procedures is the prevention of bacterial
growth/reduction of sepsis risk, in addition to CMV inactiva-
tion and prevention of alloimmunization by HLA proteins or
platelet glycoproteins. The main impediment is, as discussed,
the loss of platelet activity and clotting capacity (up to 60%);
however, this has not been reported to have any impact either
in acute transfusion reactions [74] or post-transfusion bleeding
[120].
Transfusion reactions occur less frequently in amotosalen/
UVA-inactivated PC [81], and the rate drops further when PC
are stored in a platelet additive solution III; rates of bleeding
events in recipients of these buffered platelets were lower
versus recipients who received amotosalen/UVA-treated
platelets in the same buffer, while the occurrence of infections
was not different [80]. These findings indicate that, in selected
donor populations and unstandardized PC preparation
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conditions, there is only a tiny difference in likelihood of
infectious agent transmission between inactivated and non-
inactivated preparations. The cost balance therefore has to be
individualized for each recipient and his/her health status [80,
121]. Finally, the benefits of lowering infection/
alloimmunization risk and likelihood of higher individual
bleeding risk is difficult to assess in monetary terms. The
value of an individual life is not quantifiable in any currency,
and cannot be negotiated.
Cost-effectiveness of pathogen inactivation/reduction
technologies
There have been several studies investigating the cost-
effectiveness of pathogen reduction/inactivation. In one report
(based on the UK system), the costs per life year saved for
patients aged ≤60 years using three pathogen inactivation sys-
tems (involving amotosalen/UVA, riboflavin/UVB or UVC
treatment) were estimated to range from £3.4–9.1 million
[122]. A retrospective Spanish study showed that universal
implementation of pathogen reduction (amotosalen/UVA sys-
tem) for platelet preparation from 2008 onwards extended
platelet storage time and reduced the cost associated with
out-of-date units, resulting in a saving of 13.8% of the budget
compared with the initial combined cost of platelet produc-
tion/storage/wastage for one institution [123]. In a Belgian
study, implementation of an amotosalen-based pathogen re-
duction system for platelets was found to be cost-effective
compared with the initial national system (measured in terms
of lifetime costs and quality adjusted life years (QALYs)). A
range of incremental cost-effectiveness ratios were observed
(in absence of emerging pathogens) from 3,459,201 €/QALY
to 195,364 €/QALY), and the mean threshold of emerging
infection risk for the pathogen reduction system ranged from
1/1079 to 1/2858 transfusion [124]. In addition, a model that
was developed from a Dutch study found that implementation
of pathogen inactivation as a routine procedure would be a
cost-effective measure (measuring cost-effectiveness in net
costs per life year gained (LYG)); net costs per LYG with
pathogen inactivation were estimated at €554,000 in the
baseline-weighted average over three patient groups (90%
simulation interval €354,000–1092,500). A sensitivity analy-
sis indicated that cost-effectiveness in this model was insensi-
tive to viral risks and indirect costing, but highly sensitive to
the assumption of a requirement for excess transfusions re-
quired and also discounting of life years gained. The study
authors concluded that, in view of the relatively high (and
internationally accepted) net costs per LYG for blood transfu-
sion safety interventions, the data generated by this model
indicate that pathogen inactivation may be cost-effective.
However, the study made the assumption that the pathogen
inactivation method would be 100% effective, rendering this
result uncertain [125]. In Germany (for example),
approximately 20 million € (50 € (assumed price) for
amotosalen/UVA treatment for 400,000 PC) would have to
be paid in order to prevent 6 instances of TTBI [9]. In the
USA, the cost-effectiveness of pathogen inactivation was
assessed at five institutions, comparing pathogen inactivation
costs with the costs of tests/procedures currently performed;
total potential cost savings with the implementation of patho-
gen inactivation were estimated at $141.65 per apheresis
platelet unit [126]. In the UK, approximately £1.0–3.2 million
would have to be spent in order to save 0.9–1.3 LYG per unit
when using amotosalen/UVA inactivation to reduce bacterial
contamination of platelets [122].
Another potential cost-saving approach would be to pre-
pare blood components from inactivated whole blood, treated
by an agent such as riboflavin/UVB; studies have shown that
whole blood treated with this method is safe for transfusion
use, as are its components [59, 65, 127]. This approach may
have merit in countries which rely on whole blood as their
main transfusion source. However, it should be noted that
the process of pathogen inactivation of whole blood by
riboflavin/UVB has not yet been optimized, and that some
non-enveloped viruses (e.g. hepatitis A virus) may be poorly
inactivated. Therefore, the overall cost-effectiveness of this
approach (when the potential cost of treating patients for
TTI is taken into account) has yet to be determined.
Governing bodies for blood transfusion practices
Organizations such as the European Directorate for the
Quality of Medicines and Healthcare (EDQM) support the
right of access to good quality medicines/healthcare. This in-
cludes the safe/ethical ‘collection, preparation, storage, distri-
bution and appropriate use of blood components (for) blood
transfusion’ according to their recommended quality stan-
dards [29]. Within the EDQM, the relevant committees are
the European Committee on Blood Transfusion (CD-P-TS)
and the Committee on Quality Assurance in Blood
Transfusion Services (GTS). The recommendations of these
committees are in keeping with those published by the FDA
[30, 32, 128]. The blood transfusion programme recommend-
ed by these committees is focused on three main principles:
the importance of voluntary (non-remunerated) blood dona-
tion, the goal of self-sufficiency in meeting the demand for
blood products and the need to protect both blood donors and
recipients from any potential harm. However, there is current-
ly no consensus position as to preferred pathogen reduction/
inactivation technologies [31]. The EDQM has made a series
of recommendations over the years designed to encourage
further investigation into the safety, clinical usefulness and
cost-effectiveness of pathogen reduction/inactivation technol-
ogy [30, 33]. Similar recommendations were published by the
FDA and AABB in 2015 [35, 129].
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Table 2 International/national guidelines for physicians when informing haemophilia patients of pathogen transmission risk; highlighting the
variability of how this important information is handled
Geographical
region/
country
Guidelines Source
World World Federation of Hemophilia (WFH) guidelines for the management of
haemophilia:
On the choice of products for haemophilia and related disorders: ‘The WFH
strongly recommends the use of viral-inactivated plasma-derived or
recombinant concentrates in preference to cryoprecipitate [Author’s note:
cryoprecipitate harbours a high risk of viral contamination] or fresh frozen
plasma for the treatment of haemophilia and other inherited bleeding
disorders.....[Author’s note: harbours a high risk of hypervoluminemia]
When selecting plasma-derived concentrates, consideration needs to be given to
both the plasma quality and the manufacturing process. Two issues deserve
special consideration:
Purity of product
Viral inactivation/elimination’
Section 4.1, Guidelines for the management of hemophilia
[134]
On pathogen safety: ‘The new challenge remains emerging and re-emerging
infections, many of which are not amenable to current risk reduction measures.
These include the non-lipid enveloped viruses and prions, for which diagnosis
and elimination methods are still a challenge.’
Section 6.3, Guidelines for the management of hemophilia
[134]
Germany Clinical guideline for the use of blood and blood-derived products:
‘The responsible physician must obtain the patient’s informed consent before
starting a transfusion.’
Contents of patient information are not further specified.
Cross-sectional guidelines for therapy with blood
components and plasma derivatives [135]
Guideline on the preparation and use of blood and blood-derived products:
(Translation) ‘Blood components and plasma derivatives are prescription items
and shall be subject to medical prescription. The indication must be considered
thoroughly and with careful consideration of the individual patient. […]
Informed consent should be obtained at the earliest possible time in order to
allow the patient sufficient time before consent.’
Section 4.3, Richtlinien zur Gewinnung von Blut und
Blutbestandteilen und zur Anwendung von
Blutprodukten (Hämotherapie) [43]
(Translation) ‘If informed consent cannot be obtained, e.g. in emergency
situations, patients shall be informed retrospectively about the administration of
blood products and their risks, in particular infection and immunization risks.’
Section 4.3.10, Richtlinien zur Gewinnung von Blut und
Blutbestandteilen und zur Anwendung von
Blutprodukten (Hämotherapie) [43]
Italy Recommendations for the transfusion of plasma and platelets
‘In all cases, it is recommended that the patient and/or his/her parents/tutors
receive detailed and clear information concerning the available therapeutic
approaches and replacement products, in order to achieve shared decisions and
the written informed consent for treatment and the choice of the product.’
Italian Society of Transfusion Medicine and
Immunohaematology (SIMTI) Working Party [136]
Patient consent:
The patient consent form includes a detailed description of the different levels of
pathogenic risk arising from different products for treating bleeding disorders,
and requires the patients to confirm that they have understood and agreed to
these risks.
Informed consent form for haemophilia treaters of Italy
(Consenso Informato e informativa) [137]
Spain Transfusion recipients are required to provide informed consent and information
on pathogen risk is given within the informed consent form. However, no
specific recommendations are provided pertaining to how physicians should
advise patients on pathogen risk.
Estándares en Transfusión Sanguínea – Fundacion CAT (4th
edition) [138]
Informed consent form for transfusion (Son Espases
University Hospital, Spain) [139]
UK Patient information and consent for transfusion
‘Where possible, patients (and for children, those with parental responsibility)
should have the risks, benefits and alternatives to transfusion explained to them
in a timely and understandable manner. Standardized patient information, such
as national patient information leaflets, should be used wherever possible’
Table 4.1, Handbook of transfusion medicine (5th Ed) [24]
The Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO)
recommends that ‘valid consent’ for blood transfusion should be obtained and
documented in the clinical record. The following recommendations apply:
‘Use of standardized sources of information for all patients in the UK – appropriate
information leaflets are available from the UK Transfusion Services and should
be used in all hospitals.’
Section 4.4, Handbook of transfusion medicine (5th Ed) [24]
‘Use of a standardized information resource for clinicians, indicating the key areas
to be discussed when obtaining consent – an example is available from
http://www.transfusionguidelines.org.uk/index.asp?
Publication=BBT&Section=22&pageid=7691
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A report on the collection, testing and use of blood and
blood/plasma components in Europe was issued by the
EDQM in 2010; this report provided information on pathogen
reduction/inactivation technology utilization across 33 mem-
ber states in Europe (72% of all member states) [32].
Leukodepletion was carried out for all RBC-containing prod-
ucts, plasma for transfusion and platelet concentrates in 38%
(12/32 states), 38% (9/24 states) and 56% (18/32 states) of
respondents, respectively. Irradiation of blood components
was also conducted in some cases (primarily to eliminate con-
tamination with any residual living leukocytes) but irradiated
products were restricted to at-risk patients only, e.g. immuno-
compromised individuals, who have a greater risk of develop-
ing graft versus host disease. National use of a quarantine
stage and SD and MB-L treatment is also described in the
report. In total, 24% (7/29 states) employed quarantine only,
19% (5/27 states) utilized pathogen reduction/inactivation
technology almost exclusively and 6% (2/31 states) used a
combination of the two methods [32].
Communicating residual pathogen risk to patients
Up to this point, we have described current strategies for min-
imizing the risk to patients in terms of pathogen transmission,
while striking an appropriate balance of maintaining efficacy
and keeping processing costs within reasonable limits. An
important consideration is how this information should be
presented to patients when describing the risks and benefits
when obtaining informed consent [130, 131] This information
has to be relayed in words/terms that the patients can readily
understand, so that they may become aware of all potential
consequences of transfusion, preferably using an established
communication strategy [130–132]. It may be beneficial to
define the possible risk of transfusion in relation to risk in
general (such as the risk of lightning strike [1 in107] or death
by road accident [1 in 8000] [132]) in such a way as to avoid
any misunderstanding [130].
In general, the consent procedure for every kind of blood or
plasma transfusion should include:
1. A description of the risks as well as benefits of treatment,
and listing of alternative approaches (including non-
treatment)
2. The opportunity to ask questions at any time
3. The right to accept or refuse the proposed treatment [29,
133, 134]
Patients should understand that despite improvements in
donor screening, testing methods and pathogen removal tech-
niques, the risk of pathogen transmission cannot be complete-
ly eliminated (as explained above). The extent to which pa-
tients should be further informed about specific risks depends
on a variety of factors, including the urgency of treatment,
Table 2 (continued)
Geographical
region/
country
Guidelines Source
http://www.transfusionguidelines.org.uk/index.asp?Publication=
BBT&Section=22&pageid=7691.’
‘Patients needing long-term transfusion support should have a modified form of
consent (e.g. annual review and re-consent) and this should be specified in local
policies.’
US Guidance on informed consent for blood transfusion:
‘…..at a minimum, elements of the consent shall include the following: (1) a
description of the risks, benefits, and treatment alternatives (including
non-treatment), (2) the opportunity to ask questions, and (3) the right to accept
or refuse transfusion.’
Friedman et al. [140]
Guidance on blood donation:
‘Elements of the donation procedure shall be explained to the prospective donor in
understandable terms. The explanation shall include information about risks of
the procedure, tests performed to reduce the risks of transmission of infectious
diseases to the allogeneic recipient and requirements to report donor
information, including test results, to state or local health departments. The
donor shall have an opportunity to ask questions and have them answered and
to give or refuse consent for donation. In the case of a minor or a legally
incompetent adult, consent shall be addressed in accordance with applicable
law.’
AABB standards for blood banks and transfusion services,
26th edition [141]
Information regarding attitudes, practices and training on informed consent for
transfusions and procedures:
‘60% of respondents (medical students and physicians in the US) felt that their
informed consent training was adequate. Multiple areas of difficulty in
obtaining proper informed consent were identified that should be addressed
with focused training or written guidelines.’
Vossoughi SR et al. [142]
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availability of alternative treatments, the pathogenic risk asso-
ciated with the particular product and, finally, patient capacity
(including age, physical/mental condition, education and level
of understanding, language barriers and religious beliefs).
Ethical considerations of the risk of transfusion treatment must
be respected as well [91, 130]. In emergency situations, ad-
ministration of blood- and plasma-derived products may be
justified without the patient’s consent if it is judged to be in
their best interests according to available information and
standards. However, patients should be informed about the
potential risks of such emergency treatments as soon as
possible.
For long-term treatments, such as prophylactic factor re-
placement or repeated transfusions, the provision of accurate
information relating to pathogen transmission is of utmost
importance. Information should be regularly made available,
at the first treatment and all other treatment sessions. Care
should also be taken to make patients aware of information
updates and novel products with comparable or better patho-
genic risk profiles. In their Guidelines for the Management of
Hemophilia, the World Federation of Hemophilia (WFH)
states that the core team providing care for a haemophilia
patient must include at least one member whose role is to
provide educational assistance for the patient and their family
[133, 134]. In many cases, this role will fall to the physician;
therefore, it follows that physicians would benefit from having
access to guidance on how best to convey treatment-related
information to patients [130], so that both the physician and
patient (or the patient’s family) may discuss and agree upon
the most appropriate course of treatment. The guidelines for
providing information to patients with haemophilia vary ac-
cording to region; details from selected countries are presented
in Table 2. It is the recommendation of the authors that all
physicians should ensure that they are fully informed and
aware of local guidance before counselling patients. The cur-
rent local guidelines for providing patient information are gen-
erally clear, but we feel that they would benefit from a harmo-
nization of approach: possibly in the form of international
guidelines.
Conclusion
Since the residual risk of transmission of a blood-borne infec-
tious agent by blood, blood-derived cellular products or
plasma-derived products is never zero, it is prudent to reduce
the risk of transmission as far as possible. Only accepting
blood from pre-screened donors is the first step towards re-
ducing risk, but further processing measures are still required,
as unknown pathogens may still potentially be present or new-
ly emerge. Selection of appropriate therapeutic products can
also help to reduce the residual risk, i.e. choosing a blood
component that is less likely to harbour a pathogen, or
selecting a product which has not been exposed to blood or
plasma at all. There are a variety of effective pathogen
inactivation/reduction procedures available. Implementation
of such procedures therefore has to be balanced by consider-
ations of efficacy, health benefit and potential side effects and,
finally, financial perspectives.
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